Renal Denervation vs. Pharmacotherapy for Resistant and Uncontrolled Hypertension: A Systematic Review of Cost-effectiveness Analyses
Vol. 67 No. 3 (2026), Reviews
Vol. 67 No. 3 (2026)

Renal Denervation vs. Pharmacotherapy for Resistant and Uncontrolled Hypertension: A Systematic Review of Cost-effectiveness Analyses

Reviews
Published 2026-10-15
Hamid Ostadebrahimi
Department of Pediatric, School of Medicine, Rafsanjan University of Medical Sciences, Iran
Mahsa Tashakori-Miyanroudi
Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran
Ali Khodadadizadeh
Social Determinants of Health Research Center, School of Nursing and Midwifery, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Aghdas Souresrafil
Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Iran
PDF

Keywords

Renal Denervation
Cost-effectiveness
Hypertension
Pharmacotherapy

Abstract

Introduction. Cardiovascular morbidity and mortality are associated with hypertension. Catheter-based renal denervation has been successfully used to treat resistant hypertension. The present study aimed to evaluate the cost-effectiveness of RDN compared with standard medical therapy in patients with resistant (RH) and uncontrolled hypertension (UH).

Methods. Literature searches were performed in PubMed, EMBASE, Web of science, Scopus and google scholar for full economic evaluations on RDN in patients with resistant and uncontrolled hypertension published between 1990 and 2026. Articles were screened for relevance based on preset inclusion and exclusion criteria. Final Studies in the review graded using the Quality of Health Economic Studies (QHES) instrument.

Results. A total of 43 articles were identified using our defined criteria. Two types of studies were identified: cost-effectiveness studies and cost-utility studies, the majority of which were cost-utility studies (69%). The average quality score was 89.6 (range 65-95). Treatment with RDN resulted in a 30% reduction in cardiovascular mortality. The lowest and highest incremental cost per quality adjusted life years for patients with UH were observed in Canada ($10,055.5) and Taiwan ($63,802.35), respectively. These values for patients with RH were reported in the Netherlands ($2,187.5) and Australia ($39,613).

Conclusion. The results of this systematic review indicate that RDN is a cost-effective intervention in most cost-effectiveness models. In order to more accurately estimate the economic value of RDN, future research based on long-term clinical data and in diverse health system settings is necessary.

PDF

References

Schiffrin EL, Fisher NDL. Diagnosis and management of resistant hypertension. BMJ 2024;385:e079108. https://doi.org/10.1136/bmj-2023-079108.

Flack JM, Buhnerkempe MG, Moore KT. Resistant Hypertension: Disease Burden and Emerging Treatment Options. Curr Hypertens Rep 2024;26:183-99. https://doi.org/10.1007/s11906-023-01282-0.

Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart 2019;105:98-105. https://doi.org/10.1136/heartjnl-2018-313599.

Mancia G, Cappuccio FP, Burnier M, Coca A, Persu A, Borghi C, Kreutz R, Sanner B. Perspectives on improving blood pressure control to reduce the clinical and economic burden of hypertension. J Intern Med 2023;294:251-68. https://doi.org/10.1111/joim.13678.

Cluett JL, Blazek O, Brown AL, East C, Ferdinand KC, Fisher NDL, Ford CD, Griffin KA, Mena-Hurtado CI, Sarathy H, Vongpatanasin W, Townsend RR, American Heart Association Council on H, Council on C, Stroke N, Council on the Kidney in Cardiovascular D, Council on Peripheral Vascular D. Renal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2024;81:e135-e48. https://doi.org/10.1161/HYP.0000000000000240.

Sharp ASP, Sanderson A, Hansell N, Reddish K, Miller P, Moss J, Schmieder RE, McCool R. Renal denervation for uncontrolled hypertension: a systematic review and meta-analysis examining multiple subgroups. J Hypertens 2024;4:1133-44. https://doi.org/10.1097/HJH.0000000000003727.

Schmieder RE. Renal denervation in patients with chronic kidney disease: current evidence and future perspectives. Nephrol Dial Transplant 2023;38:1089-96. https://doi.org/10.1093/ndt/gfac189.

Lauder L, Burkard T, Mahfoud F. Balancing affordability and need: should we use renal denervation in hypertension management? J Soc Cardiovasc Angiogr Interv 2024;3(10). https://doi.org/10.1016/j.jscai.2024.102248.

Adnan M, Naveed H, Hamza M, Khalid B, Safdar W, Basit J, Nassar S, Upreti P, Zafar M, Javeed Z, Prince M, Sattar Y, Alraies MC. Efficacy of renal denervation with and without antihypertensives in patients with resistant hypertension: A systematic review and meta-analysis. Nefrología 2025;45:501333. https://doi.org/10.1016/j.nefro.2025.501333.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS medicine 2021;18:e1003583. https://doi.org/10.1371/journal.pmed.1003583.

Shemilt I, James T, Marcello M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence & Policy 2010;6:51-9. https://doi.org/10.1332/174426410x482999.

Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW, Hay JW. Examining the value and quality of health economic analyses: implications of utilizing the QHES. JMCP 2003;9:53-61. https://doi.org/10.18553/jmcp.2003.9.1.53.

Xursandov I, Raximberganov J, Rakhmatova M, Jalolova M, Oripov F, Boyjanov N, Abdullayev D. Cost-effectiveness of renal denervation vs. pharmacotherapy for treatment-resistant hypertension in low-resource settings. Revista Latinoamericana de Hipertension 2025;20:644-50. https://doi.org/10.5281/zenodo.17295278.

Taylor RS, Murphy K, Kirson N, Pfefferkorn J, Kirtane AJ, Azizi M, Neumann P. Cost-Utility Analysis of Endovascular Ultrasound Renal Denervation to Treat Resistant Hypertension in the United States. J Soc Cardiovasc Angiogr Interv 2025;4:103601. https://doi.org/10.1016/j.jscai.2025.103601.

Taylor RS, Metcalfe K, Cremer A, Brouwers S, Daemen J, Carter S, Murphy K, Morice MC, Durand-Zaleski I, Ngo L, Azizi M, Kirtane AJ. Cost-Effectiveness of Ultrasound Renal Denervation for Resistant Hypertension in Belgium, France and The Netherlands. PharmacoEconomics - open 2025;9:585-95. https://doi.org/10.1007/s41669-025-00574-2.

McFarlane PA, Madan M, Ryschon AM, Tobe S, Schiffrin EL, Padwal RS, Feldman R, Dresser G, Machan L, Sadri H, Cao KN, Pietzsch JB. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Canada. J Med Econ 2025;28(1):70-80. https://doi.org/10.1080/13696998.2024.2441072.

Lian D, Suo Y, Gai R, Li N, Ren Y, Xiao D, Zhao J, Zhang M, Liu S, Chen Y. Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand. Health economics review 2025;15:69. https://doi.org/10.1186/s13561-025-00669-w.

Kahan T, Johansen ML, Ryschon AM, Cao KN, Kolovetsios MD, Lindgren P, Pietzsch JB. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden. Blood pressure 2025;34:2487583. https://doi.org/10.1080/08037051.2025.2487583.

Huang HC, Cao KN, Ryschon AM, Phay KW, Wang TD, Pietzsch JB. Cost-Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates. J of Clin Hypertens 2025;27:e70090. https://doi.org/10.1111/jch.70090.

Daemen J, Saville KA, Ryschon AM, Cao KN, van Kuijck J, Spiering W, Pietzsch JB. Cost-effectiveness of radiofrequency renal denervation for uncontrolled and resistant hypertension in The Netherlands. Blood pressure 2025;34:2573034. https://doi.org/10.1080/08037051.2025.2573034.

Taylor RS, Bentley A, Metcalfe K, Lobo MD, Kirtane AJ, Azizi M, Clark C, Murphy K, Boer JH, van Keep M, Ta AT, Barman NC, Schwab G, Akehurst R, Schmieder RE. Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension. PharmacoEconomics - open 2024;8:525-37. https://doi.org/10.1007/s41669-024-00472-z.

Sharp ASP, Cao KN, Esler MD, Kandzari DE, Lobo MD, Schmieder RE, Pietzsch JB. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence. Eur Heart J Qual Care Clin Outcomes 2024;10:698-708. https://doi.org/10.1093/ehjqcco/qcae001.

Rodriguez-Leor O, Ryschon AM, Cao KN, Jaen-Aguila F, Garcia-Camarero T, Mansilla-Morales C, Kolovetsios M, Alvarez-Orozco M, Garcia-Donaire JA, Pietzsch JB. Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain. REC Interv Cardiol 2024;6:305-12. https://doi.org/10.24875/RECICE.M24000475.

Kario K, Cao KN, Tanaka Y, Ryschon AM, Pietzsch JB. Cost-Effectiveness of Radiofrequency Renal Denervation for Uncontrolled Hypertension in Japan. J of Clin Hypertens 2024;26:1502-12. https://doi.org/10.1111/jch.14922.

Kandzari DE, Cao KN, Ryschon AM, Sharp ASP, Pietzsch JB. Catheter-Based Radiofrequency Renal Denervation in the United States: A Cost-Effectiveness Analysis Based on Contemporary Evidence. J Soc Cardiovasc Angiogr Interv 2024;3:102234. https://doi.org/10.1016/j.jscai.2024.102234.

Chowdhury EK, Reid CM, Zomer E, Kelly DJ, Liew D. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario. American journal of hypertension 2018;31:1156-63. https://doi.org/10.1093/ajh/hpy108.

Bulsei J, Darlington M, Durand-Zaleski I, Azizi M, Group DS. How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. Blood pressure 2018;27:66-72. https://doi.org/10.1080/08037051.2017.1394160.

Henry TL, De Brouwer BF, Van Keep MM, Blankestijn PJ, Bots ML, Koffijberg H. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. J Med Econ 2015;18:76-87. https://doi.org/10.3111/13696998.2014.978453.

Gladwell D, Henry T, Cook M, Akehurst R. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Applied health economics and health policy 2014;12:611-22. https://doi.org/10.1007/s40258-014-0116-7.

Dorenkamp M, Bonaventura K, Leber AW, Boldt J, Sohns C, Boldt LH, Haverkamp W, Frei U, Roser M. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J 2013;34:451-61. https://doi.org/10.1093/eurheartj/ehs355.

Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, Pietzsch JB. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol 2012;60:1271-7. https://doi.org/10.1016/j.jacc.2012.07.029.

Schmieder RE, Ryschon AM, Sharp ASP, Pietzsch J. Cost-effectiveness of RF RDN in ESC Hypertension guideline-recommended indications in six European countries: an analysis based on Global SYMPLICITY Registry DEFINE data. Eur Heart J 2025;46(S1). https://doi.org/10.1093/eurheartj/ehaf784.3408.

Eusse CA, Vanegas Cardona DM, Tenorio CA. EE8 Radiofrequency Renal Denervation for Uncontrolled Hypertension: A Cost-Effectiveness Analysis Based on the SPYRAL HTN-ON MED Trial for the Colombian Healthcare System. Value Health 2025;28:S63. https://doi.org/10.1016/j.jval.2025.04.300.

Ryschon AM, Cao K, Vanacker J, Drieghe B, Van der Heyden J, de Backer T, Pietzsch J. Radiofrequency Renal Denervation for Uncontrolled Hypertension: A Cost-Effectiveness Analysis for the Belgian Setting Based on SPYRAL HTN-ON MED and Other Contemporary Evidence. Value Health 2024;27:S56. https://doi.org/10.1016/j.jval.2024.10.301.

Pietzsch JB, Cao K, Ryschon AM, van Kuijck J, Spiering W, Daemen J. EE694 A Cost-Effectiveness Analysis of Radiofrequency Renal Denervation for Uncontrolled Hypertension Based on the SPYRAL HTN-ON Med Trial in the Netherlands. Value Health 2024;27S191-S2. https://doi.org/10.1016/j.jval.2024.10.974.

Lobo MD, Coa K, Ryschon AM, Sharp ASP, Pietzsch JB. Abstracts from the 2023 Annual Scientific Meeting of the British and Irish Hypertension Society (BIHS). J Hum Hypertens 2024;37(S1):1-36. https://doi.org/10.1038/s41371-024-00908-3.

Kahan T, Johansen ML, Ryschon AM, Cao K, Kolovetsios M, Lindgren P, Pietzsch J. EE738 Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension: An Analysis for Sweden Based on the SPYRAL HTN-ON MED Trial and Other Contemporary Evidence. Value Health 2023;26:S196-S7. https://doi.org/10.1016/j.jval.2023.09.1003.

Feldman R, Ryschon A, Cao K, Sadri H, Tobe S, Schiffrin E, Padwal R, Machan L, Pietzsch J. Cost-Effectiveness of Radiofrequency Renal Denervation for Treatment of Uncontrolled Hypertension: A Canadian Perspective. Can J Diabetes 2023;47:S153. https://doi.org/10.1016/j.jcjd.2023.10.288.

Sharp ASP, Cao K, Lobo MD, Pietzsch J. Abstracts from the 2022 Annual Scientific Meeting of the British and Irish Hypertension Society (BIHS). J Hum Hypertens 2022;36(S1):1-22. https://doi.org/10.1038/s41371-022-00734-5.

Kirtane A, Boer JH, Schmeider RE. CRT-300.15 Cost-Effectiveness of Ultrasound Renal Denervation in Patients With Resistant Hypertension. JACC: Cardiovascular Interventions 2022;15:S36. https://doi.org/10.1016/j.jcin.2022.01.171.

Arbel Y, Borohovitz A, Leshno M. Cost-Effectiveness of New Generation Renal Denervation Technologies for Resistant Hypertension. J Am Coll Cardiol 2022;79:597. https://doi.org/10.1016/s0735-1097(22)01588-1.

Pietzsch JB, Geisler BP, Schmieder RE. Pmd107 - Cost-Effectiveness Analysis of Next Generation Renal Denervation Therapy Devices: Threshold Analysis and Projections of the Spyral Htn-on Med Trial for Germany. Value Health 2018;21:S261. https://doi.org/10.1016/j.jval.2018.09.1556.

Pietzsch JB, Geisler B, Schmieder R, Egan B. Cost-effectiveness threshold analysis of various age and systolic blood pressure reduction scenarios for renal denervation therapy. EuroIntervention 2016:476.

Weber M, Hale B, Hertz D, Armstrong S, Gray W. Clinical and Cost Effectiveness of Renal Denervation with the Vessix System in Patients with Resistant Hypertension. J Am Coll Cardiol 2014;63:A2082. https://doi.org/10.1016/s0735-1097(14)62085-4.

Tilden D, McBride M, Whitbourn R, Krum H, Walton T, Gillespie J. Cost Effectiveness of Catheter-Based Renal Denervation for Treatment Resistant Hypertension - an Australian Payer Perspective. Value Health 2014;17:A762. https://doi.org/10.1016/j.jval.2014.08.266.

Sapoval M, Hale BC, Armstrong S, Hertz D, Briggs A. Cost-effectiveness of catheter-based renal sympathetic denervation for treating resistant essential hypertension in Germany. EuroIntervention 2014. https://doi.org/10.1093/eurheartj/ehs355.

Kang HY, Suh HS, Kim HS, Kang YJ, Lee H. Economic Evaluation of Catheter-Based Renal Denervation for Patients with Resistant Hypertension in Korea. Value Health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2014;17:A762. https://doi.org/10.1016/j.jval.2014.08.265.

Henry T, De BB, Van KM, Blankestijn PJ, Bots ML, Koffijberg H. Cost Effectiveness Of Renal Denervation Therapy For The Treatment Of Resistant Hypertension In The Netherlands. Value Health 2014;17:A490. https://doi.org/10.1016/j.jval.2014.08.1445.

Valencia JE, Diaz-Sotelo OD, Alfonso-Cristancho R, Barbosa Castro T, Pietzsch JB. Cost-effectiveness analysis of catheter based renal denervation (RDN) for resistant arterial hypertension in Colombia. Value Health 2013;16(3):A286. https://doi.org/10.1016/j.jval.2013.03.1484.

Sadri H, Pietzsch JB, Geisler BP, Padwal R, Vallée M, Feldman RD. Cost-effectiveness of catheter-based renal denervation for resistant hypertension – a canadian perspective. Value Health 2013;16:A284-A5. https://doi.org/10.1016/j.jval.2013.03.1477.

Jugrin AV, Caekelbergh K, Vanacker J, Vancauwenberghe L, Lamotte M. The Cost-Utility of Catheter-Based Renal Denervation as Compared to Current Standard of Care for Resistant Hypertension in Belgium. Value Health 2013;16:A527-A8. https://doi.org/10.1016/j.jval.2013.08.1291.

Ceballos RM, Sanchez-Kiobashi R, Gay JG, Pietzsch JB, Geisler BP. Health-Economic Assessment of the Use of Catheter-Based Renal Denervation in Patients with Resistant Hypertension in Mexico. Value Health 2013;16:A705. https://doi.org/10.1016/j.jval.2013.08.2154.

Pietzsch JB, Geisler BP, Akehurst RL. PMD23 Long-Term Clinical Effectiveness and Cost-Effectiveness of Catheter-Based Renal Denervation in the UK. A Model-Based Projection Based on the Symplicity HTN-2 Trial. Value Health 2012;15:A349. https://doi.org/10.1016/j.jval.2012.08.872.

Pietzsch JB, Geisler B, Esler M. Efficacy and Clinical and Economic Effectiveness in Resistant Hypertensive Subgroups. J Am Coll Cardiol 2012;59:E1716. https://doi.org/10.1016/s0735-1097(12)61717-3.

Ribichini FL, Ryschon AM, Tacconi E, Weber SA, Taddei S, Pietzsch JB. Cost-Effectiveness and Budget Impact Analysis of Radiofrequency Renal Denervation for Uncontrolled and Resistant Hypertension in Italy. High Blood Press Cardiovasc Prev 2026. https://doi.org/10.1007/s40292-026-00810-8.